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o r i g i n a l a r t i c l e
Bacterial Infections in Neonates Following Mupirocin-Based MRSA
Decolonization: A Multicenter Cohort Study
Rebecca Pierce, MS, BSN;1 Kristina Bryant, MD;2 Alexis Elward, MD, MPH;3 Justin Lessler, PhD;1
Aaron M. Milstone, MD, MHS1,4
objective. To characterize the risk of infection after MRSA decolonization with intranasal mupirocin.
design. Multicenter, retrospective cohort study.
setting. Tertiary care neonatal intensive care units (NICUs) from 3 urban hospitals in the United States ranging in size from 45 to 100 beds.
methods. MRSA-colonized neonates were identiﬁed from NICU admissions occurring from January 2007 to December 2014, during which
a targeted decolonization strategy was used for MRSA control. In 2 time-to-event analyses, MRSA-colonized neonates were observed from the
date of the ﬁrst MRSA-positive surveillance screen until (1) the ﬁrst occurrence of novel gram-positive cocci in sterile culture or discharge or (2)
the ﬁrst occurrence of novel gram-negative bacilli in sterile culture or discharge. Mupirocin exposure was treated as time varying.
results. A total of 522 MRSA-colonized neonates were identiﬁed from 16,144 neonates admitted to site NICUs. Of the MRSA-colonized
neonates, 384 (74%) received mupirocin. Average time from positive culture to mupirocin treatment was 3.5 days (standard deviation, 7.2 days).
The adjusted hazard of gram-positive cocci infection was 64% lower among mupirocin-exposed versus mupirocin-unexposed neonates (hazard
ratio, 0.36; 95% conﬁdence interval [CI], 0.17–0.76), whereas the adjusted hazard ratio of gram-negative bacilli infection comparing mupirocin-
exposed and -unexposed neonates was 1.05 (95% CI, 0.42–2.62).
conclusions. In this multicentered cohort of MRSA-colonized neonates, mupirocin-based decolonization treatment appeared to decrease
the risk of infection with select gram-positive organisms as intended, and the treatment was not signiﬁcantly associated with risk of subsequent
infections with organisms not covered by mupirocin’s spectrum of activity.
Infect Control Hosp Epidemiol 2017;1–7
Staphylococcus aureus is the second most common cause of
healthcare-associated infections (HAIs) in hospitalized neo-
nates and remains a leading cause of morbidity and excess cost
in pediatric settings.1–3 Decolonization is a strategy to prevent
S. aureus by reducing the bioburden of skin colonization that
may otherwise increase risk of subsequent S. aureus infection
or transmission. In neonatal intensive care units (NICUs),
decolonization primarily has been used to control epidemic
and endemic methicillin-resistant S. aureus (MRSA).2
Mupirocin (pseudomonic acid A), a topical antibiotic, is a
widely used decolonizing agent and is typically administered in
the nares twice daily for 5 days. Mupirocin is highly active
against staphylococci and streptococci, but it has poor in vitro
activity against gram-negative bacilli.4,5
Despite calls for more expansive use of mupirocin-based
decolonization as a prophylactic infection prevention tool,6
few studies have evaluated possible unintended consequences
of this approach.7 One potential unintended outcome is
pathogen replacement, which is addressed in mupirocin
(Bactroban) prescribing information via the caution that
application “may result in overgrowth of nonsusceptible
microorganisms” but only with prolonged use.8 Increased
susceptibility to infection after systemic antibiotic exposure
has been well described in the microbiome literature.9,10
Antibiotics may either select for or provide sufﬁcient disrup-
tion of the protective microbiota to facilitate infections with
other pathogens. There is mounting concern that mupirocin,
with its speciﬁcity for gram-positive organisms, may facilitate
infection with nontargeted, gram-negative pathogens.2,11–13
Gram-negative bacilli are signiﬁcant NICU pathogens14; they
are associated with high morbidity and mortality as well as
treatment challenges secondary to high-levels of antimicrobial
resistance.15 The possibility of organism replacement after
topical antibiotic ointment is particularly salient for infants in
Afﬁliations: 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 2. Department of Pediatrics,
University of Louisville School of Medicine, Louisville, Kentucky; 3. Department of Pediatrics, Washington University School of Medicine, St Louis, Missouri;
4. Department of Pediatrics, Division of Pediatric Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland.
© 2017 by The Society for Healthcare Epidemiology of America. All rights reserved. DOI: 10.1017/ice.2017.108
Received February 16, 2017; accepted April 24, 2017
infection control & hospital epidemiology
https://www.cambridge.org/core/terms. https://doi.org/10.1017/ice.2017.108
Downloaded from https://www.cambridge.org/core. Washington University St. Louis, on 30 Jul 2017 at 21:49:01, subject to the Cambridge Core terms of use, available at
the NICU, as they are subject to recurrent pathogen intro-
duction events from the healthcare setting and are particularly
vulnerable to infections due to naive immune systems, a
nascent microbiome, poor skin integrity, and frequent use of
invasive devices.1,16,17
Our objective was to characterize the intended and unin-
tended outcomes associated with mupirocin use amongMRSA
carriers in the NICU by estimating (1) the risk of infection
with targeted, gram-positive cocci and (2) the risk of infection
with nontargeted, gram-negative bacilli.
materials and methods
Study Design and Population
We conducted a retrospective, multicenter cohort study from
January 2007 to December 2014. Data were obtained from 3
tertiary-care NICUs for the portion of the study period when a
targeted MRSA decolonization program was employed for
MRSA control. Detailed facility data are available in Table 1.
We included neonates who were identiﬁed as MRSA-colonized
by surveillance culture and were, therefore, eligible for deco-
lonization treatment. In addition to decolonization, sites
employed other standard elements of NICU infection control
practice, including contact precautions for neonates positive
for MRSA or other multidrug-resistant organisms and chlor-
hexidine (CHG) bathing for neonates of higher gestational age
(typically >36 weeks).
Deﬁnitions and Data Collection
MRSA-colonized neonates were identiﬁed via weekly nasal
surveillance cultures conducted as part of a targeted decolo-
nization strategy, for which the protocol has been described
previously.18 Neonates entered study observation on the date
of ﬁrst positive MRSA nasal surveillance culture and were
followed until outcome occurrence or discharge.
We considered 2 outcomes for 2 separate time-to-event
analyses. Outcomes included composites of organisms that
were either covered by mupirocin’s spectrum of activity
(analysis 1) or were not (analysis 2). In analysis 1, we
characterized the occurrence of novel gram-positive cocci in
sterile culture. This included staphylococci and streptococci
species, organisms covered by mupirocin. In analysis 2, we
observed neonates for the occurrence of novel gram-negative
bacilli in sterile culture. This outcome included Enter-
obacteriaceae and other gram-negative rods (eg, Pseudomonas
spp. and Acinetobacter spp.) not covered by mupirocin’s
spectrum of activity. Outcomes were ascertained from clinical
cultures obtained during routine care in the NICU. Sterile sites
included blood, urine (obtained from urine catheter), cere-
brospinal ﬂuid, abscess ﬂuid, and pleural ﬂuid. Neonates were
followed for the novel occurrence of an outcome organism in
sterile culture, meaning that neonates were observed only for
outcome organism species that had not already been detected
in clinical culture prior to study entry. This accounted for the
possibility of multiple, distinct infections with organisms of
interest during admission and eliminated those that originated
prior to study entry. For example, in analysis 2, if a neonate
was admitted to the NICU with a Klebsiella pneumoniae–
positive clinical culture and subsequently became MRSA
colonized, then he or she would be followed for the occurrence
of a non–Klebsiella pneumoniae gram-negative organism.
Because neonates who had a pre–study-entry positive culture
with an outcome organism may have and increased or
decreased risk of additional infection with another species
within the same outcome type, we included the occurrence of
any pre-entry gram-positive cocci or gram-negative bacilli in
clinical culture as a potential confounding variable in analysis 1
and analysis 2, respectively. In sensitivity analyses, we
restricted our analysis to neonates that were free of all outcome
organisms prior to study entry.
Our primary exposure was intranasal mupirocin adminis-
tration. Mupirocin exposure information was obtained from
administrative databases and chart review. A patient was clas-
siﬁed as nonexposed from date of ﬁrst positive MRSA nasal
surveillance culture to date of ﬁrst mupirocin exposure, after
which they were considered mupirocin exposed.
Additional sensitivity analyses were performed for each
time-to-event analysis to explore the construction of compo-
site outcomes. First, we restricted outcomes to include only
bloodstream infections (BSIs) to assess whether our effects
were robust when holding the outcome specimen source
constant. We additionally conducted a post-hoc sensitivity
table 1. Study Site Descriptiona







Site 1 (St Louis, MO) Jan 2007–Dec 2014 75 5,653 233 9,523 9,308
Site 2 (Louisville, KY) Aug 2009–Nov 2013 100 4,303 185 5,649 5,932
Site 3 (Baltimore, MD) Jan 2007–Dec 2014 45 6,188 104 3,009 3,111
Total … 16,144 522 18,181 18,351
aCalendar time refers to the time period during which targeted decolonization was in place for each site. Admissions reﬂects neonate admissions
during the calendar time period. MRSA-colonized neonates identiﬁed during the relevant calendar time that had at least one day of follow up
were included in the analytic population. Analysis 1 is a survival analysis of time to gram-positive cocci infection and Analysis 2 is a survival
analysis of time to gram-negative bacilli infection.
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analysis in which we further assessed the impact of character-
izing outcomes with different organism and specimen type
combinations to ensure consistency of results.
Statistical Methods
Bivariate associations between study variables and mupirocin
exposure were assessed using χ2, Fisher’s exact, and nonpara-
metric tests. Crude incidence rates were calculated. We con-
ducted survival analyses using Cox proportional hazards
regression to assess differences in the occurrence and timing of
infection by mupirocin receipt. Mupirocin exposure was time
varying as described above. Time at risk was calculated from
the date of ﬁrst MRSA positive culture to outcome or dis-
charge, resulting in risk set comparisons being among those
with similar time since initial MRSA-colonization and, there-
fore, start of eligibility for mupirocin. A priori confounders of
interest included calendar year, prestudy entry length of stay,
gestational age, birth weight, occurrence of an outcome
organism in culture prior to study entry (described above), and
study site. The proportional hazards assumption was tested by
assessment of Schoenfeld residuals and tests of interaction of
primary study variables with time. Data were analyzed using
STATA v13.1 (StataCorp, College Station, TX) and R v3.2.1
(R Foundation for Statistical Computing, Vienna, Austria).
results
Characteristics of the Study Population
Of 16,144 total neonates admitted to site NICUs throughout the
study period, we identiﬁed 522 (3.2%) MRSA-colonized
neonates. Among these, 246 (47%) were female. Race compo-
sition was 59% white, 34% black, and 7% unknown or other.
Mupirocin treatment was administered to 380 (73%) of MRSA-
colonized neonates between ﬁrst identiﬁcation of colonization
and discharge or outcome occurrence in analysis 1 and 384
(74%) in analysis 2. Compliance for mupirocin administration
afterMRSA-positive surveillance screen ranged by site from 69%
to 79%. Average time to mupirocin receipt among those treated
was 3.5 days (standard deviation, 7.2 days). Distribution of study
variables by mupirocin exposure are presented in Table 2.
Primary Survival Analyses
Overall, 37 novel gram-positive cocci infection events were
detected during the study period, corresponding to an
incidence rate (IR) of 2.0 per 1,000 patient days. The rate of
novel gram-positive cocci infection was 64% lower for
mupirocin-exposed neonates than for mupirocin-unexposed
neonates (1.4 vs 3.9 infections per 1,000 patient days;
P= .001). Median follow-up time was 22 days (interquartile
range [IQR], 8–45 days). The adjusted hazard of gram-positive
cocci infection was 64% lower among mupirocin-exposed
versus mupirocin-unexposed neonates (HR, 0.36; 95% CI,
0.17–0.76), controlling for length of stay prior to study entry,
calendar year, birth weight, gestational age, study site, and
whether a gram-positive cocci organism had been identiﬁed
prior to study entry (Table 3A). Table 2 shows the distribution
of observed gram-positive outcome organisms and sterile
specimen types by mupirocin exposure. Outcomes included
coagulase-negative staphylococci (51%), S. aureus (35%),
streptococci (14%). Blood cultures were the most common
sterile specimen type, accounting for 22 (59%) observed
outcomes.
In total, 29 novel gram-negative bacilli infection events were
observed, corresponding to a rate of 1.6 per 1,000 patient days.
Median follow-up time was 23 days (IQR, 8–49 days). The
crude IR of novel gram-negative bacilli infection was not
signiﬁcantly different among mupirocin-exposed and -unex-
posed neonates (incidence rate ratio [IRR],1.19; 95% CI, 0.49–
3.31). Similarly, the adjusted hazard ratio of gram-negative
bacilli infection comparing mupirocin-exposed andmupirocin-
unexposed neonates was 1.05 (95% CI, 0.42–2.62), controlling
for length of stay prior to study entry, calendar year, birth
weight, gestational age, study site, and whether a gram-negative
organism had been identiﬁed prior to study entry (Table 3B).
Gram-negative organism and specimen type distribution are
shown in Table 2. Enterobacteriaceae, most notably Klebsiella
spp. (38%), Escherichia coli (21%), and Enterobacter spp. (14%),
were most common. Urine cultures accounted for 21 (72%) of
observed gram-negative bacilli outcomes.
Visual inspection of Schoenfeld residuals and tests of
interaction of mupirocin exposure with time revealed no evi-
dence that the proportional-hazards assumption had been
violated, and no signiﬁcant time-dependent effects were noted.
Sensitivity Analyses
When restricting to only neonates free of any gram-positive
cocci organisms in clinical culture prior to study entry
(n= 439), the effect of mupirocin exposure on gram-positive
cocci infection risk remained highly protective (HR, 0.30;
95% CI, 0.13–0.66). Mupirocin exposure was associated with a
nonsigniﬁcant protective effect on the hazard of gram-negative
bacilli infection among neonates without any gram-negative
bacilli identiﬁed prior to study entry (n= 479; HR, 0.81;
95% CI, 0.32–2.03).
Additional sensitivity analyses ensured consistency of results
when restricting the specimen-type and pathogen components
included in composite outcomes. First, outcomes were restric-
ted to those found in blood culture alone. The hazard of gram-
positive cocci BSI was lower among mupirocin-exposed
neonates (HR, 0.37; 95% CI, 0.15–0.88) than in those mupir-
ocin-unexposed, a ﬁnding consistent with that for the primary
outcome including all sterile specimen sites. The hazard of BSI
with gram-negative organisms was, again, not signiﬁcantly dif-
ferent among mupirocin-exposed versus -unexposed neonates
(HR, 0.82; 95% CI, 0.15–4.36). We further assessed the
robustness of our ﬁndings when altering the organism or
sterile specimen type combinations that deﬁned outcomes.
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Results were highly robust irrespective of organism or specimen
type, demonstrating a strong protective effect for organisms
covered by mupirocin (S. aureus, coagulase-negative
staphylococci, streptococci) and hazard ratios that approach 1
for noncovered organisms. Notably, the rate of S. aureus BSI
was lower among mupirocin-exposed neonates (IRR= 0.10,
table 2. Characteristics of Study Populationa


















Gram-positive cocci event 19 (5) 18 (13) .002 Gram-negative bacilli event 22 (6) 7 (5) .77
No event 361 (95) 124 (87) No event 362 (94) 131 (95)
Event specimen types Event specimen types
Blood 10 (53) 12 (66) .67a Blood 6 (27) 2 (29) 1.00b
Urine 5 (26) 3 (17) Urine 16 (73) 5 (71)
Other 4 (21) 3 (17) Other 0 (0) 0 (0)
Event organisms Event organisms
coNS 10 (53) 9 (50) .28a Acinetobacter spp. 1 (5) 0 (0) 1.00b
S. aureus 5 (26) 8 (44) Enterobacteriaceae 19 (86) 6 (86)
Streptococcus spp. 4 (21) 1 (6) Pseudomonas spp. 2 (9) 1 (14)
Previous gram-positive
cocci in culture
55 (14) 28 (20) .15 Previous gram-negative
bacilli in culture
37 (10) 6 (4) .05
No previous gram-
positive cocci in culture
325 (86) 114 (80) No previous gram-negative
bacilli in culture
347 (90) 132 (96)
LOS prior to study entry,
d (median IQR)
18 (26) 15 (31) .08b LOS prior to study entry
(days) median (IQR)
18 (26) 17 (31) .22c
Gestational age, weeks
(median IQR)
30 (9) 32 (10) .38b Gestational age (weeks)
median (IQR)
30 (9) 32 (10) .20c
Birth weight, g (median
IQR)
1,100 (949) 1,083 (836) .71b Birth weight, g (median
(IQR)
1,080 (938) 1,120 (884) .91c
Site 1 180 (47) 53 (37) .12 Site 1 183 (48) 50 (36) .06
Site 2 127 (33) 58 (41) Site 2 127 (33) 58 (42)
Site 3 73 (19) 31 (22) Site 3 74 (19) 30 (22)
NOTE. coNS, coagulase-negative staphylococci; LOS, length of stay; IQR, interquartile range.
aCharacteristics of study population shown by receipt of mupirocin while under observation for each of the speciﬁed outcomes. Specimen type
and organism variables show distribution of composite outcomes. Other sites refer to sterile sites other than blood and urine, including
cerebrospinal ﬂuid, abscess ﬂuid, and pleural ﬂuid. Previous gram-positive cocci and gram-negative bacilli in culture variables refer to the
occurrence of positive culture with any outcome organisms (speciﬁc to each analysis) prior to study entry (see text). P values obtained by
chi-square test unless otherwise speciﬁed.
bP value obtained by Fisher’s exact test.
cP value obtained by Kruskal-Wallis test.
table 3a. Clinical Characteristics Associated With Risk of Gram-Positive Cocci Infection Among
MRSA-Colonized Neonates Eligible for Mupirocin Treatment (Analysis 1)a
Variable HR 95% CI aHR 95% CI
Mupirocin treatment 0.43 0.21–0.86 0.36 0.17–0.76
LOS prior to study entry, d 0.99 0.98–1.01 0.98 0.97–1.00
Calendar year 0.94 0.80–1.10 1.00 0.85–1.18
Previous gram-positive cocci in culture 1.03 0.47–2.26 0.93 0.40–2.17
Birth weight, d 1.00 0.99–1.00 1.00 0.99–1.00
Gestational age, weeks 0.94 0.88–1.02 0.89 0.76–1.02
Site
Site 1 0.86 0.45–1.65 0.72 0.30–1.72
Site 2 0.79 0.38–1.64 0.79 0.24–2.58
Site 3 (Ref) … … … …
NOTE. MRSA, methicillin-resistance Staphylococcus aureus; HR, hazard ratio; aHR, adjusted hazard ratio;
CI, conﬁdence interval; LOS, length of stay.
aEstimates obtained via Cox proportional hazards regression. Infection outcomes as measured by novel
occurrence of positive sterile site culture with any of speciﬁed organisms.
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95% CI: 0.01-0.51) as was the hazard of S. aureus BSI in Cox
regression analysis (HR= 0.21, 95% CI: 0.04-1.26), though the
later was at trend level signiﬁcance. Additional organisms not
covered by mupirocin spectrum activity were included here,
including fungi, Propionibacterium spp., enterococci, and Cor-
ynebacterium spp. We did not ﬁnd any evidence of a signiﬁcant
increase in risk of infection when these additional, noncovered
organisms were included as outcomes. Results are shown in
Supplementary Figure 1.
discussion
Data from this large, multicenter cohort suggest that mupir-
ocin treatment for S. aureus decolonization decreases the risk
of infection with select gram-positive organisms. This ﬁnding
is consistent with other NICU studies that report reduced risk
of MRSA or methicillin-sensitive S. aureus after mupirocin
treatment.19–21 We did not ﬁnd a statistically signiﬁcant
increase in the risk of infection with gram-negative bacilli
among MRSA-colonized NICU patients treated with mupir-
ocin. These ﬁndings were robust to the type of sterile specimen
source used to identify outcomes.
This study addresses growing concern that decolonization
treatmentmay disrupt themicrobiologic ecology of the nares and
predispose neonates to infections with other organisms. Gram-
negative pathogens are of particular concern as they account for a
substantial portion of HAIs in the NICU and are associated with
high morbidity and mortality.1,14,22 In the current study, we did
not observe a signiﬁcant increase in the proportion, rate, or
hazard of gram-negative bacilli infections with mupirocin treat-
ment. In contrast, Perez-Fontan et al23 previously reported an
increase of gram-negative infections with nasal mupirocin use in
adult peritoneal dialysis patients.23 Similarly, the Mupirocin
Study Group24 conducted a randomized trial of mupirocin use in
peritoneal dialysis patients and noted increased occurrence of
gram-negative or mixed organism infections. A meta-analysis by
van Rijen et al13 pooled data from 3 trials of surgical and peri-
toneal dialysis patients and found an increased risk of infection
with non–S. aureus organisms in those who had received
mupirocin treatment. However, adult populations studied to
date are likely to be highly distinct from a neonatal population in
terms of risk factors, healthcare-associated and outpatient
pathogen exposures, as well as microbiome development.
Our study informs distal infectious outcomes associated with
mupirocin use as we observed neonates for the duration of their
NICU stay, which ranged from days to months. Additional
research is needed to assess the more immediate impact of
topical antibiotics at the level of the microbiome in hospitalized
patients, who may be more susceptible to replacement via
repeated exposure to a wide range of healthcare-associated
pathogens. Studies of the gut microbiome have shown that
antibiotic treatment can disrupt microbial communities and
can place recipients at increased risk for colonization with
opportunistic pathogens.25 However, the impact of disruptions
in the skin microbiome following antimicrobial use remains
poorly understood,26 particularly for the relatively ubiquitous
topical antibiotics. Use of triple antimicrobial ointments has
been associated with Candida colonization and infection in
adult ICU patients.27 However, a recent study of 15 adults, both
outpatient and ICU patients, found that microbial richness did
not differ pre- versus postmupirocin treatment, while S. aureus
body-site colonization decreased over time.28 The assessment of
this issue in neonates remains important because it is possible
mupirocin-driven dysbiosis is occurring but is undetectable
when clinical infection is the outcome of interest. This factor
may be particularly relevant because neonatal microbiomes are
evolving and perturbations may impact their long-term com-
position and stability.
Strengths of our study include the use of data from 3 NICUs
that utilize targeted decolonization for MRSA control. The
multicentered approach increased the capacity to identify
MRSA-colonized and mupirocin-eligible neonates that could
table 3b. Clinical Characteristics Associated With Risk of Gram-Negative Bacilli Infection Among
MRSA-Colonized Neonates Eligible for Mupirocin Treatment (Analysis 2)
Variable HR 95% CI aHR 95% CI
Mupirocin treatment 1.13 0.47–2.76 1.05 0.42–2.62
LOS prior to study entry, d 1.00 0.99–1.01 0.99 0.98–1.01
Calendar year 1.01 0.84–1.21 1.04 0.87–1.26
Previous gram-negative bacilli in culture 1.53 0.95–4.86 1.63 0.53–4.98
Birth weight, g 1.00 0.99–1.01 1.00 0.99–1.00
Gestational age, weeks 0.91 0.83–1.00 0.90 0.74–1.10
Site
Site 1 0.95 0.37–2.43 0.94 0.34–2.66
Site 2 0.56 0.18–1.75 0.62 0.14–2.67
Site 3 (Ref) … … … …
NOTE. MRSA, methicillin-resistance Staphylococcus aureus; HR, hazard ratio; aHR, adjusted hazard ratio;
CI, conﬁdence interval; LOS, length of stay.
aEstimates obtained via Cox proportional hazards regression. Infection outcomes as measured by novel
occurrence of positive sterile site culture with any of speciﬁed organisms.
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be observed for both intended and unintended infectious
outcomes after mupirocin treatment. The longitudinal nature
of the data allowed for estimates of individual-level risk of
bacterial infections associated with mupirocin use, accounting
for time at risk and establishing temporality between exposure
and outcomes. In addition, we accounted for the time-varying
nature of mupirocin exposure. This was important as mupir-
ocin was not immediately administered in all cases and
characterization of this time as mupirocin-exposed would have
underestimated the rate of infection, and therefore, also would
be underestimated the relative risk of infection associated with
mupirocin exposure. The ﬁndings of this study support prior
work demonstrating that characterization of time-varying
antibiotic exposures has important implications for inter-
preting antimicrobial-associated infection risk.29
Our study has several limitations. First, this was an observa-
tional study, and we cannot rule out residual confounding.
Although we were not aware of any systematic causes for
withheld mupirocin-based decolonization treatment, we
attempted to address this issue by comparing only MRSA-
colonized neonates at the same time from identiﬁcation of
colonization to maximize comparability between exposure
groups. Models were adjusted to control for potential
confounders. In particular, adjustment for gestational age,
calendar time, and site served to address unit CHG use, secular
trends in infection control practice over the study period, and
variation in practice by site. Although notable confounding by
these variables was not observed, results nevertheless should be
interpreted in the context of ongoing, unit-based infection
control practices. Postmupirocin infection risk may vary in
settings where these practices are not in use. A second limitation
is the reliance on clinical culture proxy to deﬁne clinically
apparent infection outcomes. We limited outcomes to positive
sterile site cultures to improve conﬁdence that we were mea-
suring true infection, but this was not veriﬁed by chart review.
Recognizing that coagulase-negative staphylococci culture
positives may, in some cases, reﬂect skin colonization as
opposed to infection, we performed sensitivity analyses focusing
on S. aureus alone and found a signiﬁcant decrease in overall
rate of S. aureus between exposure groups, suggesting that the
observed effect was not entirely driven by decreased occurrence
of coagulase-negative staphylococci. Third, we continued to
observe neonates that had a gram-positive cocci or gram-
negative bacilli positive clinical culture prior to study entry for
the occurrence of remaining species of outcome organisms. We
did so not only to avoid inclusion of infections that originated
prior to the beginning of observation but also because an early
infection with one organism would not necessarily preclude
subsequent risk of overgrowth and infection by another
organism. In doing so, we reduce outcome possibilities in
neonates with organisms of interest prior to study entry; how-
ever, given that we did not observe a signiﬁcant decrease in the
number of events in this subset, we believe this limitation is
outweighed by the risk of excluding a potentially high risk
group. Moreover, ﬁndings were consistent irrespective of the
inclusion or exclusion of these neonates. Finally, the absence of
a signiﬁcant ﬁnding for mupirocin-associated gram-negative
bacilli infection risk does not itself demonstrate absence of an
effect. To address this issue, we conducted a post-hoc power
analysis using effect sizes obtained from the Mupirocin Study
Group.24 Given a higher proportion of infection with gram-
negative or mixed organisms in the mupirocin group (20 of
134 [15%] vs 7 of 133 [5%]; P= .01 by Fisher’s exact test)24 and
our sample size of 522 neonates, our study would have 87%
power to detect a similar effect. Further research is required to
elucidate the short- and long-term impacts of topical anti-
microbials in a neonatal population. Studies that evaluate out-
comes associated with decolonization therapy should consider
reporting the overall incidence of infections with any organism
to assess unintended consequences.
In this study, we report the risk of bacterial infections
following mupirocin decolonization in a NICU population.
Our analysis suggests that mupirocin-based decolonization
treatment does not facilitate infection with organisms not
directly targeted by the approach, but it does appear to be
working as intended by reducing risk of infection with gram-
positive organisms.
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